Key result
Vaccinate-to-live policies using higher potency FMD vaccines can feasibly align with current OIE waiting periods of 3 and 6 months, as existing time restrictions lack specific scientific rationale.
Population
Animals in FMD free countries where vaccination is not practiced
Comparison
Vaccinate-to-live policy using higher potency… vs Vaccinate-to-die policy
Design
Review
Authors
Loading...
May warrant review of FMD waiting periods with higher potency vaccines; leaves open prospective validation before policy change.
The review concludes that aligning waiting periods for vaccinate-to-live policies is feasible using higher potency FMD vaccines, challenging the current time-restricted waiting periods.
Geale et al. (2013) conducted a review in Foot-and-Mouth Disease (FMD). Vaccinate-to-live policy vs. Vaccinate-to-die policy was evaluated. Vaccinate-to-live policies using higher potency FMD vaccines can feasibly align with current OIE waiting periods of 3 and 6 months, as existing time restrictions lack specific scientific rationale.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: